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a b s t r a c t
Introduction: The absence of patient's cooperation when it comes to his/her treatment (‘‘
noncompliance’’) is typical to chronic diseases and it is signiﬁcant problem in medical practice.
The term ‘‘compliance’’ means patient's capability of strictly adhering to the recommendations
concerning the prescribed treatment. The noncompliance with drug regime is frequent case in
patients with epilepsy, it is related to increased risk of epileptic seizures' occurrence and other
undesired consequences, including increased costs in the healthcare area.
Objective: The objective of our research is assessing the interconnection between compliance
with the treatment and social-demographic and clinical factors in patients with epilepsy.
Contingent and methods: The research covers 131 consecutively included patients with
epilepsy of various social-demographic and clinical characteristics. We have utilized analy-
sis of the medical documentation, anamnesis, study of the somatic and neurological status,
self-assessment scales and statistical methods.
Results: We established statistically signiﬁcant positive correlations between the number of
patients with poor compliance and the absence of professional/educational occupation,
frequency of epileptic seizures, number of the antiepileptic drugs taken during the present
and past treatment, the simultaneous presence of poor control of epileptic seizures and
adverse drug events being the reason behind the modiﬁcation of the previous treatment.
Conclusion: Patient's poor compliance, the great frequency of seizures, the higher number of
antiepileptic drugs and the adverse drug reactions have negative impact on the course of the
epileptic disease. The improved compliance results in optimizing the antiepileptic treat-
ment, improving patients' condition and signiﬁcantly cutting down costs incurred in the
healthcare area.
© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
Available online at www.sciencedirect.com
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The term ‘‘compliance’’ is patient's ability to strictly adhere to
the recommendations concerning the prescribed treatment.
The absence of compliance (‘‘noncompliance’’) is typical to
chronic diseases and it is signiﬁcant problem in medical
practice. The noncompliance with the drug regime is frequent
case when it comes to patients with epilepsy and it is related to
increased risk of epileptic seizures (ES) and other harmful
consequences, including increased costs in the healthcare
sector [1–4]. Despite the guidelines and recommendations,
many patients do not take the antiepileptic drugs (AED)
according to doctor's precise prescription. The per cent of poor
compliance with the treatment of patients with epilepsy is
high and it is observed within the limits from 20% to 80% [5–8].
The notion ‘‘noncompliance’’ includes error in the AED
dose (intake of higher or lower quantity), erroneous interval
between the individual doses, noncompliance with the treat-
ment duration, intake of AED that were not prescribed by the
doctor, noncompliance with the living regime. The compliance
degree could be formulated as per cent of the drugs taken from
the prescribed dose for particular time period [9]. The absence
of validated assessment scales creates difﬁculties when it
comes to deﬁning the impact of the speciﬁc factors on patient's
unsatisfactory compliance [10].
The adverse events (AE) and the absence of satisfactory
control of ES are the main reason for modifying the anti-
epileptic treatment. On the other hand many seizures are
being provoked directly by skipping AED. The noncompliance
signiﬁcantly deteriorates disease progression [11] and is
directly related to poor therapeutic reaction, increased disease
rate, emergency examinations and hospitalizations, as well as
increased costs in the healthcare sector [2]. The non-assess-
ment of poor compliance could result in unwanted modiﬁca-
tion of antiepileptic treatment by the doctor (modiﬁcation of
drugs and doses) and in many cases it is the reason behind the
imprecise assessment of epilepsy as therapeutically resistant
[12]. This is the reason behind running unnecessary expensive
tests (for example, pre-surgical preparation), treatment with
higher number and higher doses of AED, oftentimes with
increase of toxic drug effects. That is why the adequate
therapeutic approach requires detailed information about
compliance from the patient and his/her relatives.
2. Objective
The objective of our research is to assess the interconnection
between compliance with treatment and the social-demographic
and clinical factors in patients with epilepsy.
3. Contingent and methods
The research covered 131 consecutively included patients with
epilepsy of total 449 screened middle-aged, i.e. 40.13  13.37-
year-old, of whom 57 (43.5%) male and 74 (56.5%) female. The
patients were treated and monitored in Multi-proﬁle Hospital
for Active Treatment in Neurology and Psychiatry ‘‘SaintNaum’’ in Soﬁa. The research included patients that have had
the disease for more than 1 year, without modifying the
antiepileptic treatment in the last 3 months, without comorbid
somatic, neurologic and psychiatric diseases that require
additional treatment.
We utilized analysis of the medical documentation,
anamnesis, study of the somatic and neurological status.
We assessed the signiﬁcance of the following factors: epilepsy
type (in conformity with the International Classiﬁcation of
Epilepsies from 1989), number of taken AED during the present
and past treatment, monthly frequency of ES, AE. We used
interviewing questionnaire that included 4 points for asses-
sing patient's compliance with the treatment in the last 3
months: 1) daily dose skipping; 2) modifying the AED dose; 3)
noncompliance with the AED intake regime; 4) noncompliance
with the recommended living regime (enough sleep, regular
eating habits, no alcohol use). The answer provided to each
question was assessed correspondingly with 1 (never); 2 (1–3
times monthly) and 3 (more often than 3 times monthly). With
the possible questionnaire values from 4 to 12 points, patient's
compliance was assessed as good with general value of 5 and
more points, and as unsatisfactory with less than 5 points. The
presence and frequency of AE were assessed with adapted and
validated Bulgarian version of the Liverpool Adverse Event
Proﬁle (LAEP-BG), which contains 2 subscales: ‘‘neurologic and
psychiatric side effects’’ and ‘‘non-neurological side effects’’
[13,14]. Disease's impact onto the health-related Quality of Life
(QoL) of patients was researched with the Bulgarian version
of the Quality of Life in Epilepsy Inventory – 89 (QOLIE-89
questionnaire), which consisted of seventeen subscales [15].
The higher scores indicated better QoL.
3.1. Statistical methods
Descriptive statistics was used for calculating the demographic
and clinical data, and the scores of psychometric questionnaires
QOLIE-89 and LAEP-BG subscales. The continuous variables
were presented as a mean value  standard deviation (SD),
while noncontinuous data were presented as percentages.
Differences between scores of both patient groups (with poor
and with good compliances) were calculated by nonparametric
pair Student's t-tests. The chi-square tests and Fisher exact test
were used for the categorical variables. The Spearman Rank
Correlation was calculated to evaluate the relationships of some
investigated parameters. The level of signiﬁcance was chosen at
p < 0.05. Statistical analysis was performed using the statistical
package Statistica 8.0 for Windows (Stat Soft Inc., USA).
4. Results
The participants in our research were with different seizure
frequency: seizurefree patients (48.9% without seizures in the
last 6 months) and the ones with varying resistance degree:
38.2% with up to 3 seizures monthly and 13.0% with 4 and more
seizures monthly. On the grounds of the analysis of patient's
compliance with the treatment we established that in 81.7%
of the cases the patients rendered good cooperation during
the therapeutic process. In order to deﬁne the relationship
between the ES, AEs persistence and the need of treatment
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the previous therapy. In general for all research participants
the most frequent reason behind modifying the treatment in the
past was the simultaneous presence of AEs and poor control of
ES (56.5%), followed by the single AEs presence (16.8%), and to
the least degree the reason behind the change was only ES poor
control (7.6%).
Table 1 presents patients' distribution in view of compli-
ance degree (good and poor) and the social-demographic and
clinical characteristics. We established the lack of dependency
between the compliance degree and the social-demographic
characteristics such as age, gender, family status, education.
We observed the trend of patients' number with poor
compliance increasing with the increase of disease duration
and age (Table 1).
We established statistically signiﬁcant dependency be-
tween the presence of good compliance and professional/
academic occupation. We observed that 66% of the patients
with professional/academic occupation manifest good com-
pliance with the treatment, while 58% of the unemployed are
with poor compliance (Table 1). We established statistically
signiﬁcant dependency between the compliance and the
clinical characteristics: epilepsy type, ES monthly frequency,
number of AED taken during the present and the past
treatment, and the reasons behind the modiﬁcation of the
previous treatment (Table 1). Poor compliance was observed in
54% of the patients with cryptogenic epilepsy, and in 45% of
the patients with symptomatic epilepsy and in only 1% of
those with idiopathic epilepsy. In view of seizure frequency
statistically signiﬁcant difference between the patients with
good and poor compliance in the group without ES and the one
with more than 4 ES monthly, and good compliance was
observed in 56% of the patients without seizures and in only
9% of the patients with more than 4 seizures monthly (Table 1).
It was established that the number of AED taken during the
previous and present antiepileptic treatment is the reason
behind the poor compliance (Table 1). The patients with
monotherapy show signiﬁcantly good compliance compared
to the ones that intake higher AED number. The most
prominent difference was between the two researched patient
groups (with good and with poor compliance) with mono-
therapy and with intake of 3 and more AED, while in the case of
those treated with 2 AED the difference was insigniﬁcant. We
established signiﬁcant effect of poor compliance with the AE
treatment related to the manifestation of Neurologic and
psychiatric symptoms, assessed with the LAEP-BG question-
naire. While the values of the subscale Neurologic and
psychiatric AE increase, patients' number with poor compli-
ance increases as well (Table 1).
Data analysis depending on the number of AED taken
during the present AET shows moderate positive correlation
between the number of taken AED and seizures' frequency
(Spearman Rank Correlation rs = 0.34, p < 0.05) and between
the number of AED taken and compliance (rs = 0.26, p < 0.05).
Depending on the number of AED taken during the previous
antiepileptic treatment we established strong correlation
between the number of AED taken during the previous
treatment and the reasons behind modifying the treatment
(rs = 0.69, p < 0.05), as well as the number of AED taken during
the present treatment (rs = 0.63; p < 0.001).After analysing the QoL of patients with epilepsy depending
on the compliance degree we established that the patients
with good compliance show higher average assessments in
the majority of QOLIE-89 questionnaire subscales, which are
more pronounced for the subscales ‘‘medication effects’’,
‘‘health discouragement’’, ‘‘seizure worry’’, ‘‘role limitations:
emotional’’ and ‘‘physical function’’ (Fig. 1). We did not
establish any statistically signiﬁcant differences between
the groups with good and poor compliance for the subscales
‘‘social support’’, ‘‘language’’, ‘‘attention/concentration’’ and ‘‘
overall QoL’’.
5. Discussion
In literature we have found a total of three factor types that
impact patient's compliance with antiepileptic treatment: 1)
patent-related, for example own decision, based on assessing
treatment's effectiveness, expected teratogenicity in women,
memory violations, no understanding, accidental omission or
stigmatization; 2) drug-related, for example price, AEs (adverse
cosmetic effects of drugs, their impact on sexual life, cognitive
functions), number of prescribed AED, distribution of daily
doses and 3) disease-related, for example the ES type, disease
gravity and duration [16].
This is the ﬁrst systematic research in Bulgaria for
assessing compliance depending on the social-demographic
and clinical characteristics in the general population of
patients with epilepsy. The signiﬁcance of compliance is
important because of the chronic course of the disease, the
continuous treatment, the deteriorated Q@L and patients'
adaptation. Patient's compliance with antiepileptic treatment
could be hardly measured with precision. The aimed interview
with the patient could show higher assessment of compliance
than the objective one, but this is the simplest, most
convenient and cheap method. The relative share of the
participants in our research with poor compliance is low
(18.3%), and it is lower compared to other research works
[17–21], which is probably related to the versatile social-
demographic and clinical characteristics of our patients. Our
results approximate the lower limit of the data summarized by
Tomson, according to which around 1/5 to 2/3 of the patients
with epilepsy show noncompliance [22]. Our results on the
professional occupation being the most signiﬁcant social-
demographic factor when it comes to compliance degree from
social point of view is related to the more difﬁcult professional
realization of patients with epilepsy, the possibility of ﬁnding
job, as well as the successful performance of professional and
educational obligations [23], and reﬂects the present circum-
stances in the country with high degree of general unemploy-
ment. We established that the intake of less than the
prescribed AED quantity is related to increased ES frequency
in the research participants which was established in many
more research works [19,24–26]. According to Cramer 45% of
the patients who have skipped the AED intake reported ES
[17]. In the case of our patients that take higher AED number
we established deteriorated compliance. Usually these are
cases of higher anticonvulsants doses, with more complicated
treatment scheme and more profound AEs. The better
compliance of patients with monotherapy is easy to explain
Table 1 – Social-demographic and clinical characteristics – comparison between patients with good and poor compliance.
Variables Good compliance Poor compliance Statistic test and signiﬁcance
Aetiology of epilepsy
Genetic epilepsy 24% 1% x2 (2,131) = 38.4, p < 0.05
Structural-methabolic epilepsy 46% 45%
Unknown epilepsy 30% 54%
Total 100% 100%
Seizure frequency per month
Seizure-free 56% 17% x2(2,131) = 46.7, p < 0.001
1–3 seizures 35% 54%
≥4 seizures 9% 29%
Total 100% 100%
AED number in past AET
Without previous treatment 22% 8% x2(2,131) = 34.4, p < 0.05
1 AED 30% 29%
>1 AED 48% 63%
Total 100% 100%
AED number in present AET
Monotherapy 53% 25% x2(2,131) = 28.8, p < 0.05
2 30% 33%
>3 17% 42%
Total 100% 100%
Reasons behind modifying the
previous treatment
Without previous treatment 21% 8% x2 (3,131) = 51.2, p < 0.05
Poor control of ES 9% 1%
AEs 21% 1%
AEs + poor control of ES 49% 90%
Total 100% 100%
LAEP-BG (total score)
Neurol. and psych. side effects 31.9  8.04 39.2  8.35 Unpaired t-test t = 0.98,
df = 129: p < 0.05
Non-neurological side effects 9.5  3.2 9.2  3.2 Unpaired t-test t = 0.14,
df = 129: NS
Age (years) 39.25  13.2 44.1  13.8 Unpaired t-test t = 0.37,
df = 129: NS
Duration of epilepsy 15.43  9.28 16.42  10.35 Unpaired t-test t = 0.17,
df = 129: NS
Sex
Male 45% 38% Fisher exact test: NS
Female 55% 62%
Total 100% 100%
Marital status
Living alone 40% 31% Fisher exact test: NS
Living with family 60% 69%
Total 100% 100%
Education level
Primary education 10% 17% x2(2,131) = 27.9, p < 0.05
Intermediate school 50% 58%
University degree 40% 25%
Total 100% 100%
Employment status
Employed/student 66% 42% Fisher exact test: <0.05
Unemployed 34% 58%
Total 100% 100%
Note: Data are presented as mean  SD or number of patients (%), NS – no signiﬁcance, statistical signiﬁcance p < 0.05.
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of the disease, probably the better forecast and the higher
expectations of full seizures' control correspondingly. This
thesis was supported by numerous authors [13,27–30]. Theestablished positive correlation between the number of AED
taken and the noncompliance demonstrates the critical role of
compliance when it comes to making adequate decisions and
fully realized antiepileptic treatment. Baulac outlines the
Fig. 1 – Mean scores of QOLIE subscales – comparison between patients with good and poor compliance. * statistical
significance p < 0.05.
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particular of compliance when proceeding from combined
treatment to monotherapy [31], and Matsuura assesses
patient's general satisfaction when polytherapy is being
reduced [32]. The present research work reports the interrela-
tion between the most prominent AE and the deteriorated
patient's compliance. The worries related to the manifestation
and persistence of AE oftentimes provide the occasion for
suspending the drug intake. In view of the general score of
LAEP–BG – 47.75 (SD  7.82) in our patients, the assessment
that contributes the most is the one of ‘‘neurologic and
psychiatric adverse effects’’ subscale – 32.82 (SD  7.86),
showing the great signiﬁcance of neurotoxic effects when
taking AED. The majority of the patients, especially the ones
treated with higher number and doses of AED are with
deteriorated concentration and memory, which has negative
impact on compliance [28,33,34]. Most of our participants with
great disease duration are with poor compliance, which is
probably related to age and discouragement because of
treatment effectiveness [5].
On the grounds of the results of patients with previous
antiepileptic treatment we established great signiﬁcance of
the simultaneous presence of AEs and ES being the reason
behind the unsuccessful antiepileptic treatment, deteriorated
compliance and modiﬁed therapy in the past. In the case ofpersisting ES we apply higher AED doses, and polytherapy is
more frequent with more profound AEs, the subjective feeling
of absence of wellbeing in these cases is stronger and it
deteriorates patients' QoL. In most cases the impact of the
adverse drug effects in patient's everyday life is signiﬁcantly
more profound than the presence of +S [29]. When making the
decision to change the antiepileptic treatment we should
accurately assess compliance. In the case of 34.6% of our
participants with 1–3 ES monthly and 9.3% the ones with ≥4 ES
are with better compliance, and to these patients the best
clinical solution is changing the dose or the drug. In 54.2% of
patients with 1–3 ES monthly and 29.1% of those with ≥ 4 ES
with established poor compliance, and in these cases it is
suitable to improve compliance before changing the treat-
ment. This belief is supported by the data of the previous
research works about the higher number and doses of AED in
the case of patients with poor compliance, as well as the more
frequent therapy change [4]. The optimization of drug regime
(therapeutic plan and/or two-time dose of AED), the more
frequent contact and improved communication with patients,
training of the patient and his/her relatives could signiﬁcantly
improve the compliance degree [20,35].
The notion Q@L includes the subjective sensation of well-
being and satisfaction with life and it depends on clinical,
demographic and social-economic factors. In the researched
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higher correlation with better Q@L and higher values of the
QOLIE-89 questionnaire, especially in the areas that reﬂect
drugs' effects, the discouragement in view of health, the
worries concerning the seizures, the physical functions and
emotional limitations. The adverse drug effects and ES have
negative impact on the compliance degree and QoL. The
participants with better compliance have more optimistic
attitude towards their health, they have higher QoL, better
emotional status and better physical functioning, which
supports what was established during the previous research
works [20,25,36].
The poor compliance not only has negative impact on
disease progression, but it increases treatment costs [2,11].
After reviewing the medical registers of 10 892 patients with
epilepsy in USA, Davis established that the deteriorated
compliance was related to 11% hospitalization increase and
47% emergency examinations increase hence we have signi-
ﬁcant healthcare price increase [37].
We could conclude that treatment success greatly depends
on the compliance degree, i.e. patient's capability to strictly
adhere to the drug regime for certain period of time. The
treatment that is not fully realized results in more frequent
seizures, adverse effects of AED and increased disease rate [2].
The noncompliance that remains unnoticed by the doctor
results in frequent change of the AED type, frequent increase
of the daily dose and the number of AED taken and the AEs
acceleration correspondingly. The responsibility for compli-
ance with the drug regime is comprehensive and should be
shared by the healthcare specialists, the healthcare system
and the patients [11].
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